Supplementary Data — Dornase alfa for COVID-19: real-time meta analysis of 3 studies

@CovidAnalysis, November 2025, Version 2V2
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Files (RCT) -9% 1.09 [0.61-1.92] death 39 (n) 88 (n) Improvement, RR [CI] Treatment Control I-SPY COVID Files (RCT) -32% 1.32 [0.84-2.08] no recov. 39 (n) 88 (n) COVASE Porter (RCT) -130% 2.30 [0.10-52.1] death 1/30 0/9 COVASE Porter (RCT) 53% 0.47 [0.06-3.86] death 30 (n) 69 (n) COVASE Porter (RCT) 10% 0.90 [0.11-7.63] no disch. 3/30 1/9 Åkesson (SB RCT) -11% 1.11 [0.30-4.12] death 4/36 4/40 Åkesson (SB RCT) -2% 1.02 [0.62-1.69] no recov. 36 (n) 40 (n) Dornase alfa COVID-19 outcomes c19early.org November 2025 Favors dornase alfa Favors control
Fig. S1. All outcomes.